HRD Plus combines analysis of somatic (tumor-acquired) and germline (inherited) mutations in BRCA1 and BRCA2, along with genomic instability. This combined approach provides a more comprehensive understanding of a patient’s DNA repair capability, which is useful for both treatment and family risk evaluation.
Patients with ovarian cancer who are being considered for PARP inhibitor (PARPi) therapy, as well as cases where there is a need to assess both tumor biology and inherited BRCA-related risk, thereby guiding genetic counseling and family risk evaluation.
